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Endoscopic injection sclerotherapy for bleeding varices in 
children with intrahepatic and extrahepatic portal venous 
obstruction: Benefit of injection tract embolisation
V L Bandika, E A Goddard, R De Lacey, R A Brown
Portal hypertension due to intrahepatic disease or extrahepatic portal 
vein obstruction (EHPVO) is an important cause of upper gastro-
intestinal bleeding in children. About 50% of children with EHPVO 
present with bleeding from oesophageal varices.1-3 Improvements 
in the management of children with intrahepatic disease have led 
to increased survival, consequently contributing to the long-term 
burden of portal hypertension.1, 3-5
The peak age of variceal bleeding, although not clearly defined, 
relates to a critical point where wall tension exceeds variceal wall 
strength. Other determinants of a ‘herald’ bleed include upper 
respiratory infection, fever and aspirin ingestion.6 These factors 
directly or indirectly increase portal venous pressure or result in 
fever-related tachycardia which increases cardiac output.
Since its introduction, endoscopic sclerotherapy of bleeding 
oesophageal varices, where variceal banding is not feasible, has 
remained the mainstay treatment for haemodynamically stable 
patients and where clotting abnormalities have been corrected. 
Concerns about its efficacy and safety in the management of 
oesophageal varices in children and adults have recently been 
raised. Several innovations have been aimed at improving 
sclerotherapy outcome. We prefer paravariceal injection with 
injection tract embolisation. Intravariceal injection has also been 
used. Ethanolamine oleate is our preferred sclerosant. However, 
different types of sclerosants have been used without affecting 
outcome. 
Progress has been made in developing newer endoscopic techniques 
for managing bleeding oesophageal varices which are safer, but pose 
challenges in terms of availability, cost and operative techniques. 
Endoscopic variceal band ligation is safer than sclerotherapy, 
but the diameter of the band applicator makes it impossible to 
insert the applicator into the small oesophagus of children aged 
<3 years.7 Coupled with the success and increased availability of 
liver transplantation (LT), the successful management of bleeding 
oesophageal varices in these children is required in preparation for 
LT or other appropriate surgery.
We aimed to assess whether the use of injection tract embolisation 
improves the efficacy and safety of sclerotherapy compared with 
the previously used direct injection method in the management of 
oesophageal varices where banding is not feasible. We retrospectively 
evaluated a series of children with bleeding oesophageal varices, 
treated with sclerotherapy in our centre. We analysed the outcome of 
endoscopic sclerotherapy performed with injection tract embolisation 
and its relationship to the underlying aetiology.
Methods
Between 1998 and 2007, 70 children who presented with bleeding 
oesophageal varices secondary to portal hypertension (41 with 
intrahepatic conditions and 29 with EHPVO) underwent injection 
sclerotherapy at Red Cross War Memorial Children’s Hospital. The 
patients presented with upper gastro-intestinal bleeding manifested 
as haematemesis or malaena. Resuscitation and stabilisation 
using intravenous fluids, blood, platelets and fresh-frozen plasma 
transfusions, was performed if required. An infusion of octreotide 
was administered at 1 - 5 µg/kg in a 5% dextrose solution at 5 ml/
hour, in decreasing doses over 4 - 5 days. If these measures failed to 
arrest upper gastro-intestinal bleeding, emergency endoscopy was 
performed. Failure to arrest bleeding by sclerotherapy was managed 
by placement of a Sengstaken Blakemore tube (SSBT). 
Once stable, patients underwent elective videoscope endoscopy 
under general anaesthesia. Careful endoscopic assessment of the 
foregut was performed to identify the site and true cause of bleeding. 
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Background. The outcome of sclerotherapy for bleeding oesophageal 
varices may be influenced by injection technique. In a previous 
study at our institution, sclerotherapy was associated with a high 
re-bleeding rate and oesophageal ulceration. Embolisation of the 
injection tract was introduced in an attempt to reduce injection-
related complications.
Methods. To determine the outcome and effectiveness of injection 
tract embolisation in reducing injection-related complications, we 
retrospectively reviewed a series of 59 children who underwent 
injection sclerotherapy for oesophageal varices (29 for extrahepatic 
portal vein obstruction (EHPVO) and 30 for intrahepatic disease) 
in our centre.
Results. Sclerotherapy resulted in variceal eradication in only 
11.8% of the children (mean follow-up duration: 38.4 months). 
Variceal eradication with sclerotherapy alone was achieved in 
20.7% and 3.3% of EHPVO and intrahepatic disease patients, 
respectively. Injection tract embolisation was successful in reducing 
the number of complications and re-bleeding rates. Complications 
that arose included: transient pyrexia (16.7%); deep oesophageal 
ulcers (6.7%); stricture formation (3.3%); and re-bleeding before 
variceal sclerosis (23%).
Conclusion. Injection sclerotherapy did not eradicate oesophageal 
varices in most children. Injection tract embolisation by sclerosant 
was associated with fewer complications and reduced re-bleeding 
rates.
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Patients with non-variceal upper gastro-intestinal bleeding were 
excluded from analysis.
The extent of oesophageal varices and the presence of gastric 
varices were documented; 5% ethanolamine oleate was injected as 
a sclerosant, usually 0.5 - 0.75 ml per injection, at multiple (up to 
5) sites paravariceally – enough to produce a visible blanch with 
mucosal swelling. Injection tract embolisation was performed by 
continuation of the sclerosant injection using the terminal 0.2 ml as 
the needle was withdrawn. The number of injections and amount of 
sclerosant used were noted. Subjects were admitted to a high-care 
unit following sclerotherapy and monitored for adverse effects. Repeat 
sclerotherapy was performed at 2-weekly intervals until identified 
varices were eliminated. Because the recurrence of varices depends on 
the underlying pathogenesis, further investigations were undertaken to 
identify the underlying cause of portal hypertension.
Results
The study population comprised 70 children: 29 with EHPVO and 41 
with intrahepatic causes of portal hypertension. Eleven children with 
intrahepatic disease secondary to biliary atresia were not included in 
the analysis of sclerotherapy details due to missing clinical data, but 
were included in the analysis of outcome.
Intrahepatic causes of portal hypertension included: biliary atresia 
(20); congenital hepatic fibrosis syndromes (3); neonatal hepatitis (1); 
auto-immune hepatitis (1); Alagille syndrome (1); Langerhans cell 
histiocytosis (1); and idiopathic cirrhosis (3). Clinico-demographic 
details are summarised in Table 1.
Regardless of the cause of portal hypertension, all patients had 
severe enough upper gastro-intestinal bleeding to necessitate a 
blood transfusion. Mean patient age at first sclerotherapy, presumed 
to coincide with the age at first episode of upper gastro-intestinal 
bleeding, was 3 years and 7 months.
Sclerotherapy and octreotide were effective in arresting acute 
variceal bleeding in 56/59 (94%) patients. SSBT insertion was used 
in 3 patients, and endoscopic variceal band ligation (EVBL) was 
performed in 4 of the older patients. No emergency definitive surgical 
procedure was offered.
Gastric varices were identified in 22/59 (37.3%) patients – slightly 
more than in the EHPVO group, but not statistically significant. 
Surprisingly, gastric varices were rarely found to be a cause of upper 
gastro-intestinal bleeding; no patient had any additional procedure 
to specifically address bleeding varices in the gastric region of the 
oesophageal gastric junction. Of interest is that the presence of gastric 
varices was used as an indication for selecting patients for shunt 
surgery in EHPVO.
Among children in the intrahepatic disease group, 53.3% had 
initial or first oesophageal bleeding before age 2 years, compared 
with 37.9% in the EHPVO group, although this difference was not 
statistically significant. No significant difference in the number of 
patients presenting with first variceal bleeding was noted within all 
the age categories in both groups (p>0.05). In the intrahepatic group, 
the distribution pattern of age at first variceal bleeding was related to 
the nature of the underlying disease, modification effect of therapy 
offered and subsequent course of the disease spectrum.
Sclerotherapy alone was successful in controlling the bleeding 
from oesophageal varices in 7 (11.9%) patients. However, 2 of these 
patients with EHPVO presented as re-bleeders after previous variceal 
sclerosis and were managed by additional sclerotherapy sessions. 
Eighteen of 29 (62.1%) EHPVO patients were offered surgical 
shunts. Meso-Rex shunts were the most favoured, performed on 8 
Table 1. Clinico-demographic details of patients undergoing sclerotherapy
EHPVO 
(N=29)
Intrahepatic disease
(N=30)
Gender (male:female) 20:9 10:20
Age at first sclerotherapy (months), mean (range) 42.6 (9 - 112) 43.0 (7 - 159)
Number of sclerotherapy sessions, mean
Median (range)
6.48
5 (1 - 16)
3.73
3 (1 - 11)
Number of injections to variceal sclerosis, mean
Median (range)
25.46
22 (3 - 59)
16.70
13 (3 - 52)
SSBT 0 3
Co-existent gastric varices 13 9
EHPVO = extrahepatic portal vein obstruction; SSBT = Sengstaken Blakemore tube.
Table 2. Complications of the different sclerotherapy injection techniques
Study
Hill and Bowie8 (no injection tract 
embolisation) (N=33)
n (%)
Current (injection tract embolisation, 
number of complication occurrence/total 
sclerotherapy sessions) (N=300)
n (%)
Transient pyrexia 13 (39) 50 (16.7)
Deep oesophageal ulcers 10 (30) 20 (6.7)
Stricture 4 (12) 10 (3.3)
Re-bleeding before variceal sclerosis 12 (36) 70 (23)
Confirmed sepsis - 16 (5.3%)
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patients, 2 of whom were post LT. Splenorenal and mesocaval shunts 
were offered to 6 and 4 patients, respectively.
Eleven patients underwent LT. No definitive procedure was 
offered to 7 patients who were awaiting donor availability or had a 
condition excluding them from LT at that time. Nine patients were 
lost to follow-up. Four deaths were reported, occurring during 
admission for sclerotherapy; cause of death was not directly related 
to sclerotherapy or its complications, but to the underlying disease.
Injection tract embolisation was associated with a lower 
complication rate (Table 2). A greater number of confirmed sepsis 
cases were reported among intrahepatic disease patients (17/30 
(56.7%) compared with 9/29 (31%) EHPVO patients; p=0.067). 
Organisms cultured included Escherichia coli, Staphylococcus 
epidermidis, Klebsiella species and Acinetobacter species.
Discussion
The study cohort had a nearly even distribution of EHPVO and 
intrahepatic disease as a cause of varices, allowing us to compare 
modes of sclerotherapy and determine if outcome was influenced by 
underlying aetiology.
Early portoenterostomy and LT availability have contributed to a 
higher incidence of children requiring sclerotherapy for intrahepatic 
portal hypertension compared with the Hill and Bowie8 study where 
most patients had EHPVO.
The age of first variceal bleeding in the intrahepatic group was 
determined by the underlying disease process. In this study, more 
children with intrahepatic disease than EHPVO bled within the first 
2 years of life. The reason for this is the contribution of a delayed 
diagnosis of biliary atresia in these children. Three patterns of 
intrahepatic variceal bleeding were also demonstrated: first group (0 - 
24 months) – missed biliary atresia; second group (25 - 60 months) – 
mainly attributable to poorly functioning or failed portoenterostomy; 
third group (5 - 9 years) – could be explained as a critical point where 
intrahepatic cholangiopathy effect is maximal and overrides biliary 
drainage offered by portoenterostomy, and where LT should be 
considered in children with previously ‘successful’ portoenterostomy. 
In EHPVO, there was an equal distribution of patients in the first 5 
years of life, suggesting an age-independent aetiology.
The results of our study do not support other reports showing 
sclerotherapy to be successful in both groups in eradicating 
oesophageal varices (i.e. controlling bleeding without a need for a 
definitive procedure).9,10 Only 11.8% of patients showed variceal 
eradication on sclerotherapy alone after a mean follow-up duration 
of 38.4 months. In contrast to other studies,2,9,10 the success rate 
with sclerotherapy alone on EHPVO was 20.7%, which was low. 
Most children in the successful group presented just before puberty 
and were able to re-canalise or spontaneously achieve adequate 
portosystemic collaterisation (thought to be hormonally induced), 
which could have contributed to this observation. This was possibly 
the basis of previous studies which reported success. 
Anecdotal reports have come from parents, teachers and 
paediatricians about the resolution of behavioural and cognitive 
problems after physiological surgical shunts and the low success 
rate after sclerotherapy. Meso-Rex shunt as a definitive procedure 
was recommended in this group and was offered in 35.8% of 
patients, of whom 6.5% were post LT with associated portal vein 
obstruction. There is, to date, no consensus on EHPVO management. 
Some studies advocate Meso-Rex shunt in all children with portal 
vein thrombosis and cavernous transformation.11 Early age at first 
presentation, the presence of fundal varices which are usually not 
easily amenable to sclerotherapy as shown in a previous study in 
the same setting, 12 life-threatening bleeds, numerous sclerotherapy 
sessions and failure to thrive could also be considered as indications 
for Meso-Rex shunt. Likewise, LT is the only definitive treatment in 
biliary atresia with a failed Kasai portoenterostomy.
In this series, 44.8% of EHPVO and 30% of intrahepatic disease 
patients had gastric varices. We also demonstrated primary co-existence 
of both oesophageal and gastric varices rather than the secondary 
opening of gastric collaterals after oesophageal variceal sclerosis. 
However, on endoscopy, no corresponding gastric variceal bleeding 
was noted in either group. The oesophageal variceal bleeding could 
possibly act as a ‘sump’, reducing intravariceal pressures in the gastric 
venous system. 
The largest contributor to intrahepatic portal hypertension was 
biliary atresia, which ultimately necessitated LT. Sclerotherapy was 
used to ‘buy time’ while awaiting LT, enabling 11/30 children to 
undergo LT. Endoscopic variceal band ligation has been shown to be 
superior due to fewer complications,13,14 but its use in children aged <3 
years remains technically difficult due to the diameter of the smallest 
band applicator. As in our scenario, where 53.3% of intrahepatic 
disease patients and 41.4% with EHPVO presented with variceal 
bleeding were aged <3 years, sclerotherapy and octreotide have to be 
used as a first treatment option and subsequently sclerotherapy alone 
in controlling variceal bleeding while awaiting LT or an appropriate 
shunt procedure in EHPVO. Recently, Duche et al.15 demonstrated the 
effectiveness and safety of prophylactic sclerotherapy and octreotide 
in controlling oesophageal varices in biliary atresia.
A combination of medical management using octreotide infusion 
and sclerotherapy was effective in arresting variceal bleeding in 
both groups in our study. Only 3/59 (5.1%) children required SSBT 
placement to arrest variceal bleeding, supporting previous findings.2,16
As in other studies,16,17 3 - 5 sessions of sclerotherapy at 2-weekly 
intervals were needed to achieve variceal sclerosis. In 7 children who 
showed variceal eradication with sclerotherapy alone, an additional 
2 sessions were required. The amount of sclerosant to cause visible 
blanch was 0.7 ml/injection, similar to other studies within the range 
of 0.5 - 1 ml/injection.2 The mean number of injections per session 
was 4.27, with a mean of 2.98 ml sclerosant administered per session.
Injection tract embolisation with sclerosant was successful in 
the overall reduction of complications. Hill and Bowie8 expressed 
complication rates as a one-time event which could have overestimated 
the true occurrence. We appreciate the difficulties in comparison 
due to difference in presentation of complication rates. Transient 
pyrexia, stricture, ulcers and re-bleeding before variceal sclerosis were 
less incident in our study compared with non-tract embolisation 
in the hospital’s previous series (Table 2).8 While the authors of the 
comparative study attributed the high re-bleeding rates to a high rate 
of gastric varices, we demonstrated similar high gastric variceal rates 
but these varices were not implicated as a cause of bleeding. Our high 
re-bleeding rates might have been due to slough bleeding which was 
erroneously labelled as re-bleeding. Our observed oesophageal stricture 
rate of 3.3% was lower than in other studies.8,16,17 No statistically 
significant difference was noted in endoscopy-associated bloodstream 
infections in either group, but over 50% of patients in the intrahepatic 
group had sepsis compared with 37% in the EHPVO group. This 
could be due to a probable bias in selecting patients in the intrahepatic 
group. The patients with significant liver dysfunction on presentation 
were not offered sclerotherapy, especially if they were not eligible for 
LT. Furthermore, more patients in this group died from primary liver 
disease or were lost to follow-up. The net effect was the selection of 
patients with portal hypertension from intrinsic liver disease, but 
without a significant liver dysfunction impairing immunity.
Sclerotherapy was not associated with any mortality. However, 
some patients in the intrahepatic group died from the primary 
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disease before definitive treatment was offered. The higher number 
of patients lost to follow-up in the intrahepatic group could have been 
due to patients in this group who were not eligible for LT, and either 
died at home or sought care from other health facilities.
In conclusion, a similar outcome of sclerotherapy was demonstrated 
in both groups in our study. Sclerotherapy alone was unsuccessful in 
controlling oesophageal varices in both groups. However, it was 
useful in managing acute variceal bleeding and should be offered 
as an option, particularly in the young patient where endoscopic 
variceal banding is not technically possible. We now routinely 
employ injection tract embolisation by sclerosant, which has greatly 
contributed to reducing sclerotherapy complications.
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